In San Francisco, the first day of Transcatheter Cardiovascular Therapeutics 2025 annual meeting offered presentations on the future of the convergence of devices, drugs and AI. The takeaway from the session seems to be that while the future is bright, it will become the present only when payers can find an economic argument to pay for the advances formed by this convergence.

Sustaining healthy weight loss is about so much more than cutting calories or injecting drugs, as many GLP-1 users are finding out. Withings SA continues to expand its obesity care management ecosystem and the capabilities of its connected scale to support patients through their weight loss journey and their lives after reaching goal, potentially addressing the vexing problem of patients rapidly regaining all – and often more – weight once they discontinue the drugs.

Ventyx Biosciences Inc. rolled out positive results from the phase II study with oral, once-daily VTX-3232 in patients with obesity and cardiovascular (CV) risk factors.

Two biopharma companies launched within the past year raised top amounts in series B financings for 2025, seeking to advance their therapeutic candidates for cardiovascular diseases and obesity.

A top-line readout of the 26-week phase IIa Cbeyond trial showed nimacimab, Skye Bioscience Inc.’s peripherally restricted CB1 inhibitor antibody for weight loss, fell short of statistical significance as a monotherapy vs. placebo on the primary endpoint of weight loss, sending the company’s shares down 60%. Skye executives, however, offered a more optimistic outlook for the findings, which they said provide clear direction for moving forward.

Phase IIb data of Metsera Inc.’s lead GLP-1 receptor agonist, MET-097i, showed significant weight loss and good tolerability, supporting a phase III start later this year, and validating Pfizer Inc.’s decision a week ago to buy the obesity-focused company for $7.3 billion.

Beijing QL Biopharmaceutical Co. Ltd.’s once-monthly GLP-1 receptor agonist, zovaglutide (ZT-002), met its primary and secondary endpoints in a phase II obesity trial, and QL Biopharm will now advance the GLP-1 to a pivotal phase III study.

Two recent studies should provide comfort to medical device manufacturers who develop tools and devices for bariatric surgery. Patients who undergo bariatric surgery lost nearly three times more weight than those who received prescriptions for glucagon-like peptide-1 receptor agonists (GLP-1 RA) or GLP-1/gastric inhibitory polypeptide (GIP) receptor agonists in a real-world, retrospective study published in JAMA Surgery.

Pfizer Inc. bounced back in a big way from a GLP-1 trip-up this spring by making known its plan to take over what Metsera Inc. CEO Whit Bernard has called the “scale-obsessed” obesity player that he steers. Pfizer has agreed to pay $47.50 each for all of Metsera’s outstanding shares.

Beijing QL Biopharmaceutical Co. Ltd.’s once-monthly GLP-1 receptor agonist, zovaglutide (ZT-002), met its primary and secondary endpoints in a phase II obesity trial, and QL Biopharm will now advance the GLP-1 to a pivotal phase III study.